Radiotherapy in recurrent ovarian cancer: updated results of involved-field radiation therapy

Author:

Lee Byung MinORCID,Lee Seo JinORCID,Kim NaleeORCID,Byun Hwa KyungORCID,Kim Yong BaeORCID

Abstract

ObjectiveThis study aimed to update the possible clinical benefits of radiation therapy in recurrent ovarian cancer.MethodsThe medical records of 495 patients with recurrent ovarian cancer after initially undergoing maximal cytoreductive surgery and adjuvant platinum-based chemotherapy based on the pathologic stage between January 2010 and December 2020 were analyzed: 309 and 186 patients were treated without and with involved-field radiation therapy, respectively. Involved-field radiation therapy is defined as radiation therapy only to the areas of the body involved by tumor. The prescribed doses were ≥45 Gy (equivalent dose in 2 Gy/fraction). Overall survival was compared between patients treated with and without involved-field radiation therapy. The favorable group was defined as patients who satisfied at least four of the following factors: good performance, no ascites, normal CA-125, platinum-sensitive tumor, and nodal recurrence.ResultsThe median age of the patients was 56 years (range 49–63) and median time to recurrence was 11.1 months (range 6.1–15.5). 217 patients (43.8%) were treated at a single site. Radiation therapy, performance status, CA-125, platinum sensitivity, residual disease, and ascites were all significant prognostic factors. The 3-year overall survival of all patients, patients treated without radiation therapy, and patients treated with radiation therapy was 54.0%, 44.8%, and 69.3%, respectively. Radiation therapy was associated with higher overall survival rates in the unfavorable and favorable patient groups. Patient characteristics showed higher rates of normal CA-125, lymph node metastasis only, lower platinum sensitivity, and higher rates of ascites in the radiation therapy group. After propensity score matching, the radiation therapy group showed superior overall survival to the non-radiation therapy group. Normal CA-125, good performance status, and platinum sensitivity were associated with a good prognosis in patients treated with radiation therapy.ConclusionOur study showed that higher overall survival was observed in patients treated with radiation therapy in recurrent ovarian cancer.

Funder

National R&D Program for Cancer Control of the National Cancer Cente

Publisher

BMJ

Subject

Obstetrics and Gynecology,Oncology

Reference27 articles.

1. National Cancer Centre . Korean National cancer Statistics; 2023. Available: https://ncc.re.kr/cancerStatsView.ncc?bbsnum=618&searchKey=total&searchValue=&pageNum=1

2. Defining survivorship trajectories across patients with solid tumors: an evidence-based approach;Dood;JAMA Oncol,2018

3. Armstrong DK , Backes FJ . Ovarian cancer, version 4.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022.

4. Stereotactic body radiation therapy for Oligometastatic ovarian cancer: A step toward a drug holiday;Lazzari;Int J Radiat Oncol Biol Phys,2018

5. Impact of tumor volume-directed involved field radiation therapy integrated in the management of recurrent ovarian cancer

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3